Contemporary Concise Review 2021: COVID-19 and other respiratory infections

Ken K. P. Chan1 | David S. C. Hui1,2

1Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
2Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong

Correspondence
David S. C. Hui
Email: dschui@cuhk.edu.hk

Funding information
Health and Medical Research Fund, Grant/Award Numbers: COVID1903003, COVID190126; Research Grants Council, University Grants Committee, Grant/Award Numbers: T11-712/19-N, T11-705/21-N; SH Ho Foundation

Handling Editor: Philip Bardin

Summary of key points
- Bats are likely the primary source of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Minks are highly susceptible to infection by SARS-CoV-2.
- Transmission from asymptomatic individuals was estimated to account for over 50% of all transmissions of coronavirus disease 2019 (COVID-19) cases.
- SARS-CoV-2 is evolving towards more efficient aerosol transmission.
- Remdesivir, baricitinib, tocilizumab and dexamethasone are frequently used for the treatment of patients with respiratory failure due to COVID-19.
- There is a rising incidence of non-tuberculous Mycobacterium pulmonary disease globally, with a higher prevalence in Asian countries than in the Western world.
- Protracted bacterial bronchitis is a common cause of chronic productive cough in childhood.
- Re-emergence of respiratory syncytial virus may occur after the relaxation of infection control measures and the reopening of borders during COVID-19 pandemic.

KEYWORDS
antiviral, clinical, COVID-19, respiratory infections, review

INTRODUCTION

The coronavirus disease 2019 (COVID-19) started with a cluster of pneumonia of unknown cause in Wuhan, China, at the end of 2019.1 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was rapidly identified as the culprit virus. The World Health Organization (WHO) declared COVID-19 a pandemic in March 2020. Two years after this announcement, there have been more than 5 million confirmed cases of COVID-19, including 6 million deaths, reported to the WHO.2 In this review, different aspects of COVID-19 with salient updates on other respiratory infections published mainly in 2021 are briefly reviewed.

COVID-19

Origin of SARS-CoV-2 and intermediary animal source

There is growing evidence for a bat origin of SARS-CoV-2 beyond China in Southeast Asia. Whole-genome sequences obtained from five bats (Rhinolophus acuminatus) in a cave in Thailand yielded one isolate (named RacCS203), which is mostly related to the RmYN02 isolate found in Rhinolophus malayanus in Yunnan, China. SARS-CoV-2 neutralizing antibodies were also detected in bats of the same colony and in a pangolin at a wildlife checkpoint in Southern Thailand. Antiseras raised against the receptor-binding domain (RBD) of RmYN02 was found to cross-neutralize SARS-CoV-2, although the RBD of RacCS203 or RmYN02 failed to bind angiotensin-converting enzyme (ACE) 2 receptor.3

There were outbreaks of SARS-CoV-2 in mink farms in the Netherlands and Denmark in 2020. Some cats and dogs from infected farms tested positive for the virus, but rabbits, chickens and horses sampled on several farms, and wildlife sampled near the infected mink farms were negative for SARS-CoV-2. Minks are highly susceptible to infection by SARS-CoV-2, but the routes of transmission between farms are uncertain other than through direct human contact.4

Transmission and clinical presentation

SARS-CoV-2 transmits mainly by droplets which gain entry into the respiratory tract through the ACE2 receptor. The
level of ACE2 expression in the lower respiratory tract (LRT) is increased in elderly and males, but is not related to the pack-years smoked. In a mouse model expressing human ACE2, high viral loads were detected in the lungs as early as 2 days post-infection, which reproduced the progression of COVID-19 in the LRT. The distribution of ACE2 receptors in the body is one of the determining factors of predominant symptoms presented in COVID-19.

In a decision analytical model of multiple scenarios of proportions of asymptomatic individuals with COVID-19 and infectious periods, transmission from asymptomatic individuals was estimated to account for over 50% of all transmissions. A retrospective observational study in Wuhan has shown that children and adolescents were less susceptible to SARS-CoV-2 infection, but were more infectious than older individuals within households. Presymptomatic cases were more infectious while individuals with asymptomatic infection were less infectious than symptomatic cases. The clinical spectrum of SARS-CoV-2 infection is summarized in Table 1.

Compared with late presenters (presenting to hospital ≥7 days from symptom onset), early presenters of COVID-19 (<7 days from symptom onset) were older, more likely to have significant comorbidities (hypertension, thromboembolic and renal diseases) and less likely to report cardinal symptoms including fever, cough, dyspnoea and diarrhoea. Early presenters had less infiltrates on chest x-ray while the presence of infiltrates in this group revealed an increased risk of adverse outcomes.

The duration of viral shedding may be prolonged in males, elderly, immunocompromised hosts, corticosteroid users and those with high fever, delayed hospitalization, severe or critical illnesses. The factors that affect the clinical sensitivity or specificity of SARS-CoV-2 tests include days from symptom onset, sampling site and antigen test compared with reverse transcriptase-PCR testing.

A study with air and environmental samplings has shown that SARS-CoV-2 is evolving towards more efficient aerosol transmission, and loose-fitting masks provide only modest source control. Therefore, social distancing measures and tight-fitting masks and respirators will be required until vaccination rates are very high.

A British study has shown a higher hospitalization or emergency care attendance risk for patients with COVID-19 infected with the delta variant compared with the alpha variant, while a matched controlled study in Sweden has shown COVID-19 as a risk factor for acute myocardial infarction and ischaemic stroke. A prospective, multicentre cohort study in 302 UK healthcare facilities has shown that complications and worse functional outcomes in patients hospitalized with COVID-19 are high, even in young, previously healthy individuals. Acute complications are associated with reduced ability to self-care at discharge, with neurological complications being associated with the worst functional outcomes.

A prospective, longitudinal study has shown that Long-COVID is associated with weak anti-SARS-CoV-2 antibody response, severity of illness and female gender. Late clinical events and persistent symptoms in the medium and long term occur in a significant proportion of patients hospitalized for COVID-19. A population-based cohort study using the Danish prescription and health insurance registries has shown that the absolute risk of severe post-acute complications after SARS-CoV-2 infection not requiring hospitalization is low. Nevertheless, more frequent visits to general practitioners and hospital outpatient clinics could indicate COVID-19 sequelae.

### Autopsy findings and radiological features

A large multi-institutional autopsy survey has shown that patients dying of or with COVID-19 had an average of 8.9 pathological conditions documented at autopsy, with a combination of prior chronic diseases and acute conditions acquired during hospitalization. Clinical conditions during terminal hospitalization were cited 395 times for the 135 autopsied decedents and predominantly encompassed acute failure of multiple organs and/or impaired coagulation while myocarditis was rare.

Kianzad et al. explored the relationship between the histopathological findings and the radiological patterns in eight autopsy cases, who had thorax computed tomography (CT) within 1–3 days before death. They found that the different typical CT patterns in COVID-19 were not related to specific histopathological patterns. Microvascular damage and thrombosis were even encountered in the radiologically normal lung.

Neuroimaging has revealed that localized inflammation in intracranial olfactory structures and persistent olfactory impairment with or without perceptual distortions (i.e., parosmias or phantosmias) after SARS-CoV-2 infection could serve as a marker to identify people with an increased long-term risk of neurological disease (Figure 1).

### Table 1 Clinical spectrum of SARS-CoV-2 infection

| Category | Description |
|----------|-------------|
| Asymptomatic or presymptomatic infection | Individuals who test positive for SARS-CoV-2 using a virologic test but who have no symptoms that are consistent with COVID-19. |
| Mild illness | Individuals who have any of the various signs and symptoms of COVID-19 but who do not have shortness of breath, dyspnoea or abnormal chest imaging. |
| Moderate illness | Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (SpO2) ≥ 94% on room air at sea level. |
| Severe illness | Individuals who have SpO2 < 94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300 mm Hg, respiratory rate > 30 breaths/min or lung infiltrates > 50%. |
| Critical illness | Individuals who have respiratory failure, septic shock and/or multiple organ dysfunction. |

Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Source: NIH.
Pulmonary embolism (PE) is a common complication, and systemic microangiopathy may cause profound vascular and perfusion abnormalities in the absence of PE, as found by dual-energy CT imaging. This may explain the out-of-proportion acute hypoxaemic respiratory failure in COVID-19 pneumonia.

Risk factors for severe COVID-19

Various risk factors for severe COVID-19 have been described (Table 2). Among these factors, increasing age is a strong predictor of in-hospital mortality. Asthma, although a chronic respiratory illness, is not considered a risk factor for severe COVID-19. The reduced ACE2 receptor expression in the LRT in asthma patients may be protective. In addition, environmental factors may contribute. By using the 10-year particulate matter ≤2.5 μm (PM$_{2.5}$) exposure at the residential zip code, Mendy et al. found that long-term exposure to PM$_{2.5}$ was associated with increased hospitalization in COVID-19. An et al. retrospectively analysed the association of inhaled corticosteroid (ICS) use with COVID-19 prognosis using the government health insurance system in South Korea, and revealed that the use of ICS was not associated with the hospital length of stay (LOS), intensive care unit (ICU) admission and all-cause mortality. The development of secondary bacterial infection following COVID-19 was associated with persistent fever, increased oxygen requirements, shock, increased ventilatory and organ support and higher mortality. Cytokine dysregulation has been proposed as the driver of inflammation. Among critically ill patients, monocyte chemoattractant protein-1 predicted the duration of mechanical ventilation, highest norepinephrine dose administered and length of ICU stay.

Treatment

Numerous randomized controlled trials (RCTs) on both non-pharmacological and pharmacological options for COVID-19 targeting different disease severities have been conducted.

Respiratory and oxygen support

Hypoxaemic respiratory failure is common in severe COVID-19 pneumonia. During the COVID-19 outbreak, non-invasive respiratory support, including high-flow nasal cannula (HFNC), continuous positive airway pressure and non-invasive ventilation (NIV), is a feasible strategy to cope with the massive demand for ventilatory assistance outside the ICU. In severe COVID-19 pneumonia, the choice between HFNC and NIV does not alter the subsequent need for intubation at 48 h. A negative-pressure, well-ventilated room with at least 12 air exchanges per hour would be ideal to remove any infectious aerosols.
Jones et al. identified spontaneously breathing patients who were indicated for proning (required supplemental oxygen or was tachypnoeic) in a retrospective analysis. The majority of these patients received supplemental oxygen via nasal prongs only. There was no evidence of reproducible response to proning and no relationship between the effect of proning on first treatment with subsequent treatments. In a subsequent RCT involving 1126 patients who required respiratory support with HFNC for acute hypoxaemic respiratory failure due to COVID-19, it was found that awake prone positioning reduced the incidence of treatment failure and the need for intubation without any signal of harm.

Pharmacological options

Pharmacological aspects can be further subdivided into early antiviral treatment and late immunomodulatory treatment, which combat against the direct viral effect (high viral load) and cytokine dysregulation (hyper-inflammation causing further organ damage), respectively.

Among recently exposed, asymptomatic individuals, both bamlanivimab/etesevimab or casirivimab/imdevimab combinations were effective post-exposure prophylaxis before the emergence of Omicron. These two combinations, both being neutralizing monoclonal antibodies that target the surface spike glycoprotein of SARS-CoV-2 which mediates viral entry into host cells, reduced the incidence of symptomatic COVID-19, with an absolute risk difference of −6.6% and −13.3%, respectively, when compared with placebo. In non-hospitalized patients with mild to moderate COVID-19 and a high risk for progression to severe disease, both intravenous bamlanivimab/etesevimab and casirivimab/imdevimab within 3 days after a laboratory diagnosis of COVID-19 can reduce the incidence of COVID-19-related hospitalization and death from any cause (relative risk reduction: bamlanivimab/etesevimab 70%; casirivimab/imdevimab 2400 mg group 71.3%; casirivimab/imdevimab 1200 mg group 70.4%), and enhance the decline in viral load at day 7 before the emergence of Omicron. However, these monoclonal antibodies are no longer distributed due to lack of efficacy against the Omicron.

In hospitalized COVID-19 patients with LRT involvement, remdesivir, a broad-spectrum anti-RNA virus nucleoside analogue originally designed for Middle East respiratory syndrome coronavirus and Ebola virus, is the first antiviral agent endorsed and repurposed for COVID-19. Dexamethasone, as an immunomodulatory agent, is indicated for moderate or severe COVID-19. In the RECOVERY trial, dexamethasone 6 mg daily up to 10 days resulted in lower 28-day mortality in patients who were receiving either invasive mechanical ventilation (IMV) or oxygen alone at randomization but not among those receiving no respiratory support.

The other two effective immunomodulatory agents are tocilizumab (a monoclonal antibody against the IL-6 receptor to counteract the elevated IL-6 levels due to immune dysregulation and hyperinflammation) and baricitinib (a Janus kinase [JAK]) inhibitor targeting the cytokine storm. The use of tocilizumab in severe COVID-19 pneumonia has induced conflicting results in several landmark trials. Two subsequent meta-analyses confirmed that the use of tocilizumab was associated with a reduction in mortality and with the need for IMV in hospitalized COVID-19 patients. While for baricitinib, it reduces the recovery time and accelerates improvement in clinical status among patients with COVID-19, especially among those receiving high-flow oxygen or NIV, and reduces mortality in those receiving IMV or extracorporeal membrane oxygenation. A meta-analysis comprising 12 studies of 3564 patients concluded that baricitinib improved the mortality rate, ICU admission, the requirement for IMV and the oxygenation index.

Azithromycin, doxycycline and colchicine have been proven ineffective in hospitalized patients in improving overall mortality, initiation of ventilation and duration of hospital stay. High-titre convalescent plasma did not improve survival or other outcome in patients hospitalized with COVID-19, but early administration appeared useful in reducing the progression of COVID-19 in mildly ill infected older adults.

Vaccination

Vaccination, in addition to community-wide interventions such as mask-wearing and social distancing, is pivotal in the battle against COVID-19. Standard vaccination of BNT162b2 (Pfizer-BioNTech), AZD1222 (Oxford AstraZeneca), mRNA-1273 (Moderna) and CoronaVac (Sinovac) all offer high vaccine effectiveness against the ancestral SARS-CoV-2 strain and the Delta variant. However, the current challenges from the Omicron variant are the waning neutralizing antibody titres with time. The booster dose provides a solution to these problems by boosting the neutralizing antibody responses.

The reasons for low vaccination uptake include vaccine hesitancy (vaccine safety and effectiveness concern), perceived scientific uncertainty, low disease risk perception, low trust in authorities and other stakeholders and global vaccine inequity (late acquisition of the vaccine in some developing countries).

Impact and transformation of health care during COVID-19

Due to the highly contagious nature of SARS-CoV-2, violation of social distancing and infection preventive measures has led to sporadic outbreaks through clustering of people in different settings, including pubs, residential care homes for the elderly, cruises and religious places. Despite effective preventive measures, social distancing has changed the daily routine of each human and the
healthcare service in the world. Surveyed American and Australian adults would consider delaying or avoiding medical care due to concerns with the COVID-19 pandemic.\textsuperscript{67} Cancer services are also delayed, with a significant projection of increased cancer death as the next wave of non-infective disease pandemic.\textsuperscript{68} The stringent infection control around aerosol-generating procedure measures also delays the set-up of NIV services for patients with type 2 respiratory failure with a subsequent increase in mortality.\textsuperscript{69} The mental health among healthcare workers is significant, with a higher prevalence of anxiety, depression and other mental illnesses than the general public in the COVID-19 pandemic. Consistent and accurate information, adequate resources and training, and physical and mental support should be proactively delivered by the governing bodies to relieve the mental stress of healthcare workers.\textsuperscript{70}

The introduction of social restriction in New Zealand led to a significant reduction in the admission of acute infectious respiratory admissions, in parallel to the drop of circulating respiratory viruses.\textsuperscript{71} Strong attention to infection control principles may limit the spread of antibiotic-resistant pathogens between patients, which may continue to benefit after the COVID-19 pandemic.\textsuperscript{72} Telemedicine was rapidly adopted as a widespread model of healthcare delivery during the early COVID-19 pandemic, but it declined when the pandemic continued. Isautier and McCaffery stressed the importance of reflecting on patients' experiences and satisfaction with telehealth when building up and maintaining the telemedicine service. Appropriate platform and mode of healthcare delivery should be modified based on the patient's need.\textsuperscript{73} While facing the difficulties of holding an in-person multidisciplinary meeting (MDM) for complex diseases such as interstitial lung disease and lung cancer, clinicians may convert the MDM to virtual format and benefit more patients through the online formation of a larger conglomerate of virtual MDMs.\textsuperscript{68,74} The improved collaboration between respiratory physicians and intensivists with optimal critical care resource use could help reduce delay in discharge and patient LOS and increase ICU bed availability.\textsuperscript{75}

OTHER RESPIRATORY INFECTIONS

MAC pulmonary disease

Recent epidemiology studies have revealed a rising incidence of non-tuberculous Mycobacterium pulmonary disease (NTM-PD) both regionally and globally, with a higher prevalence in Asian countries than the Western world.\textsuperscript{76} The presence of comorbidities is a poor prognostic factor leading to a higher hospitalization and mortality rate.\textsuperscript{77} The latest treatment guideline endorses the use of amikacin liposome inhalation suspension (ALIS) in refractory Mycobacterium avium complex (MAC)-PD, which is defined as remaining sputum culture-positive after 6 months of guideline-based therapy (GBT). In the landmark CONVERT trial, the addition of ALIS to GBT in refractory MAC-PD achieved significantly greater culture conversion by month 6 than GBT alone and the therapeutic effect could sustain and remain durable 12 months after culture conversion.\textsuperscript{78} Hearing loss and renal function abnormalities were generally similar between treatment arms in the CONVERT trial, except for more tinnitus in the ALIS arm. A subsequent open-label extension study identified no additional safety concerns.\textsuperscript{79}

Asakura et al. found that serum Krebs von den Lungen-6 (KL-6) levels were significantly higher in MAC-PD patients than in healthy controls. The serum KL-6 level was significantly associated with disease progression, together with positive acid-fast bacilli and caviatory lesions. The change in serum KL-6 was significantly higher in the disease progression group; it decreased post-treatment, reflecting the negative sputum culture conversion. This may be a potential biomarker in the future.\textsuperscript{80}

Protracted bacterial bronchitis

Protracted bacterial bronchitis (PBB) is a common cause of chronic productive cough in childhood. It is defined as a wet cough of at least 4-week duration with no identified specific cause of cough that resolved following 2–4 weeks of appropriate antibiotics.\textsuperscript{81} Childcare attendance, prior history of chronic cough and age < 2 years increased the risk of PBB following the healthcare presentation for an acute cough illness in children, while a baseline diagnosis of asthma/reactive airways disease or bronchiolitis decreased the risk.\textsuperscript{81} Clinicians and parents should be aware of the risk factors and symptoms for PBB. Such knowledge and health-seeking behaviour can be improved through education with culturally secure health information. Laird et al. have shown that the knowledge translation approach to improving recognition and management of chronic wet cough is feasible in Australian Aboriginal children.\textsuperscript{82} PBB has impact on the development of subsequent airway diseases. A prospective single-centre study found that, after the post-index PBB episode, 67.5% had ongoing symptoms and 9.6% had bronchiectasis. Significant predictors of bronchiectasis were recurrent PBB in year 1 of follow-up and the presence of *Haemophilus influenzae* in the bronchoalveolar lavage. Clinician-diagnosed asthma at final follow-up was present in 27.1% of children with PBB. Positive allergen-specific IgE at baseline and bronchomalacia were significant predictors of asthma diagnosis.\textsuperscript{83} *Moraxella catarrhalis* was the most common organism (52.4%) identified in a retrospective analysis of 903 children.\textsuperscript{81} Ruffles et al. performed the first RCT to assess the duration of antibiotic treatment in children with chronic wet cough and suspected PBB, by comparing the clinical cure (cough resolution) by day 28 between 2 and 4 weeks of amoxicillin-clavulanate. By day 28, there was no significant difference in clinical cure between the two groups, but the time to next wet cough exacerbation was significantly longer in the 4-week group than in the 2-week group.\textsuperscript{84}
Respiratory syncytial virus

Respiratory syncytial virus (RSV) is a major cause of LRT infection and hospitalization in infants. Nebulized ALX-0171, a novel trivalent nanobody with antiviral properties against RSV, has been studied on its effect in children hospitalized for RSV acute severe LRT infection. It was shown that this drug, at different doses, led to a shorter time in viral clearance, as measured by the quantifiable limit on plaque assay, but it was not translated into an improvement in clinical outcomes. In an experimental study, Liu et al. assessed lung function, airway inflammation and immunohistopathology in BALB/c mice infected by influenza, rhinovirus and RSV. They identified IL-17A, the archetype T-helper cell 17 (Th17) cytokine, as the common pathogenic molecule regulating the disease induced by the three viruses, and they induced severe airway constriction and inflammation 2 days post-infection. The neutralization of IL-17A by monoclonal antibody led to a number of beneficial effects, including a substantial drop in endogenous production of IL-17A, attenuation of the increase in airway resistance induced by the viral infection, resolution of airway hyperresponsiveness and reduction in the airway infiltration of neutrophils and lymphocytes. Although there was no effect on viral replication, targeting the IL-17A may represent a novel therapeutic pathway in viral lung infections.

During the COVID-19 pandemic, the circulation of RSV, together with acute infectious respiratory admissions, has dropped due to the strict contact-restriction policy in New Zealand. However, a re-emergence of RSV is noted after the relaxation of infection control measures and the reopening of borders. Although co-infection with SARS-CoV-2 and RSV (and other respiratory viruses) is uncommon in the past 2 years, proactive measures should be prepared for this possible combination in the future.

ACKNOWLEDGEMENTS

David S. C. Hui is supported by the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR (COVID1903003 and COVID190126), RGC theme-based research schemes (T11-712/19-N and T11-705/21-N) and SH Ho Foundation.

CONFLICT OF INTEREST

None declared.

ORCID

Ken K. P. Chan https://orcid.org/0000-0002-8163-5846
David S. C. Hui https://orcid.org/0000-0003-4382-2445

REFERENCES

1. Hui DS, Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;196:264–6.

2. World Health Organization. Coronavirus (COVID-19) dashboard. [Accessed 26 May 2022.] Available from: https://covid19.who.int/.
2019 (COVID-19) pandemic: a large multi-institutional autopsy survey study. Arch Pathol Lab Med. 2021;145:529–35.
22. Kianzad A, Meijboom IJ, Nossent EJ, Roos E, Schurink B, Bonta PI, et al. COVID-19: histopathological correlates of imaging patterns on chest computed tomography. Respirology. 2021;26:869–77.
23. Yxdakis MS, Albers MW, Holbrook EH, Lyon DM, Shih RY, Frasnelli JA, et al. Post-viral effects of COVID-19 in the olfactory system and their implications. Lancet Neurol. 2021;20:753–61.
24. Idilman IS, Telli Dizman G, Ardali Duzgun S, Irmak I, Karcaaltincaba M, Inkaya AC, et al. Lung and kidney percussion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy. Eur Radiol. 2021;31:1090–9.
25. World Health Organization. Living guidance for clinical management of COVID-19. 2021 Nov 23. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2
26. King PT, Londrigan SL. The 1918 influenza and COVID-19 pandemics: the effect of age on outcomes. Respirology. 2021;26:840–4.
27. Gülseren A, König IR, Jappe U, Drömann D. Effect of comorbid pulmonary disease on the severity of COVID-19: a systematic review and meta-analysis. Respirology. 2021;26:352–65.
28. Mindy A, Wu X, Keller JL, Fassler CS, Apewokin S, Mersha TB, et al. Air pollution and the pandemic: long-term PM2.5 exposure and disease severity in COVID-19 patients. Respirology. 2021;26:1181–7.
29. An TJ, Kim Y, Park YB, Kim K, Cho DY, Yoo KH, et al. Inhaled corticosteroid is not associated with a poor prognosis in COVID-19. Respirology. 2021;26:812–5.
30. Lee SI, Koh JS, Kim YJ, Kang DH, Park D, Park HS, et al. Secondary infection among hospitalized COVID-19 patients: a retrospective cohort study in a tertiary care setting. Respirology. 2021;26:277–8.
31. Ling L, Chen Z, Lui G, Wong CK, Wong WT, Ng RWY, et al. Longitudinal cytokine profile in patients with mild to critical COVID-19. Front Immunol. 2021;12:763292.
32. Cammarota G, Esposito T, Azzolina D, Cosentini R, Menzella F, Aliberti S, et al. Noninvasive respiratory support outside the intensive care unit for acute respiratory failure related to coronavirus-19 disease: a systematic review and meta-analysis. Crit Care. 2021;25:268.
33. Nair PR, Haritha D, Behera S, Kayina CA, Maitra S, Anand RK, et al. Comparison of high-flow nasal cannula and noninvasive ventilation in acute hypoxemic respiratory failure due to severe COVID-19 pneumonia. Respir Care. 2021;66:1824–30.
34. Hamilton GS. Aerosol-generating procedures in the COVID era. Respirology. 2021;26:416–8.
35. Jones IRA, Attard Z, Bellomo R, Burgess N, Donovan A, Graco M, et al. Repeated proning in non-intubated patients with COVID-19. Respirology. 2021;26:279–80.
36. Ehrmann S, Li J, Ibarra-Estrada M, Perez Y, Pavlov I, McNicholas B, et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021;9:1387–95.
37. Shang L, Lye DC, Cao B. Contemporary narrative review of treatment options for COVID-19. Respirology. 2021;26:745–67.
38. Cevik M, Tate M, Lloyd O, Maraoio AE, Schafer J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2:e13–22.
39. Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szeprt W, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11:3136–29.
40. Cohen MS, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. JAMA. 2021;326:46–55.
41. Dougan M, Nirula A, Arizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385:1382–92.
42. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385:e81.
43. Kock G, Hillen HS, Tegunov D, Dienemann C, Seitz F, Schmitzova J, et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun. 2021;12:279.
44. RECOVERY Collaborative Group, Horby P, Lim WS, Emerson JR, Matham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.
45. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503–16.
46. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–45.
47. Kyriazopoulos C, Ntritsos G, Gogali A, Milionis H, Evangelou E, Kostikas K. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: a systematic review and meta-analysis. Respirology. 2021;26:1027–40.
48. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CI, Godolphin PJ, Fisher D, Higgins JPT, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499–518.
49. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795–807.
50. Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327–36.
51. Lin Z, Niu J, Xu Y, Qin L, Ding J, Zhou L. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2022;94:1523–34.
52. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:605–12.
53. Butler CC, Yu LM, Dorward J, Gbinigie O, Saville BR, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med. 2021;9:1010–20.
54. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021;9:1419–26.
55. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049–59.
56. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610–8.
57. Jenkins C, Sunjaya A. Social distancing as a strategy to prevent respiratory virus infections. Respirology. 2021;26:143–4.
58. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397:2331–3.
59. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397:2461–2.
60. Tang P, Hasan MR, Chehataelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27:2136–43.
61. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant
infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10:751–9.
62. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–94.
63. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–76.
64. Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. Covid-19 vaccination hesitancy. BMJ. 2021;373:n1138.
65. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626–36.
66. Waterer G, Pickens CI, Wunderink R. Antibiotic-resistant bacteria: epidemiology, clinical spectrum, viral kinetics and impact of COVID-19 in the Asia-Pacific region. Respirology. 2021;26:322–33.
67. Cieslser MÉ, Kennedy JL, Wiley JF, Facer-Childs ER, Robbins R, Barger LK, et al. Delay or avoidance of routine, urgent and emergency medical care due to concerns about COVID-19 in a region with low COVID-19 prevalence: Victoria, Australia. Respir. 2021;26:707–12.
68. Watson A, Barnard H, Antoine-Pitterson P, Jones B, Turner AM, Mukherjee R. The impact of COVID-19 on acute non-invasive ventilation services: a case for change. Respir. 2021;26:1106–9.
69. Smallwood N, Willis K. Mental health among healthcare workers during the COVID-19 pandemic. Respir. 2021;26:1016–7.
70. Waterer G, Waterer P, Rimmer D. Anti-bacterial resistant bacteria: COVID-19 hasn’t made the challenge go away. Respir. 2021;26:1024–6.
71. Isautier JMJ, McCaffrey K. Sydney Health Literacy Lab COVID-19 Group. Patients are a vital voice for the future of telehealth. Respir. 2021;26:729–30.
72. Mackintosh JA, Glenn L, Barnes H, Dunn E, Bancroft S, Reddy T, et al. Benefits of a virtual interstitial lung disease multidisciplinary meeting in the face of COVID-19. Respir. 2021;26:112–5.
73. Liu X, Nguyen TH, Sokulsky L, Li X, Garcia Netto K, Hsu AC, et al. IL-17A is a common and critical driver of impaired lung function and immunopathology induced by influenza virus, rhinovirus and respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9:21–32.
74. Liu X, Nguyen TH, Sokulsky L, Li X, Garcia Netto K, Hsu AC, et al. IL-17A is a common and critical driver of impaired lung function and immunopathology induced by influenza virus, rhinovirus and respiratory syncytial virus. Respir. 2021;26:1049–59.
75. Lindén A. IL-17A: a promising target in viral lung infections. Respir. 2021;26:1012–3.
76. van Ingen J, Obradovic M, Hassan M, Lesher B, Hart E, Chatterjee A, et al. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex – disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med. 2021;15:1387–401.
77. Mourtad A, Baker AW, Stout JE. Reduction in expected survival associated with nontuberculous mycobacterial pulmonary disease. Clin Infect Dis. 2021;72:e552–7.
78. Griffith DE, Thomson R, Fume PA, Aksamit TR, Field SK, Addirizzo-Harris DJ, et al. Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure. Chest. 2021;160:831–42.
79. Winthrop KL, Fume PA, Thomson R, Mange KC, Yuen DW, Ciesielska M, et al. Amikacin liposome inhalation suspension for MAC lung disease: a 12-month open-label extension study. Ann Am Thorac Soc. 2021;18:1147–57.
80. Azakura T, Kimizuka Y, Nishimura T, Suzuki S, Namkoong H, Masugi Y, et al. Serum Krebs von den Lungen-6 level in the disease progression and treatment of Mycobacterium avium complex lung disease. Respir. 2021;26:112–9.
81. O’Grady KF, Mahon J, Arnold D, Grimwood K, Hall KK, Goyal V, et al. Predictors of the development of protracted bacterial bronchitis following presentation to healthcare for an acute respiratory illness with cough: analysis of three cohort studies. J Clin Med. 2021;10:5735.
82. Laird P, Walker R, Lane M, Totterdell J, Chang AB, Schultz A. Recognition and management of protracted bacterial bronchitis in Australian Aboriginal children: a knowledge translation approach. Chest. 2021;159:249–58.
83. Ruffles TJ, Marchant JM, Masters IB, Yerkovich ST, Wurzel DF, Gibson PG, et al. Outcomes of protracted bacterial bronchitis in children: a 5-year prospective cohort study. Respir. 2021;26:241–8.
84. Ruffles TJ, Goyal V, Marchant JM, Masters IB, Yerkovich S, Buntain H, et al. Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children (DACS): a multi-centre, double blind, randomised controlled trial. Lancet Respir Med. 2021;9:1121–9.
85. Cunningham S, Piedra PA, Martinon-Torres F, Szymanski H, Bracke B, Dombrecht E, et al. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9:21–32.
86. Liu X, Nguyen TH, Sokulsky L, Li X, Garcia Netto K, Hsu AC, et al. IL-17A is a common and critical driver of impaired lung function and immunopathology induced by influenza virus, rhinovirus and respiratory syncytial virus. Respir. 2021;26:1049–59.
87. Lindén A. IL-17A: a promising target in viral lung infections. Respir. 2021;26:1012–3.
88. Uhlig K, Amadi A, Forman M, Mostafa HH. Circulation of non-SARS-CoV-2 respiratory pathogens and coinfection with SARS-CoV-2 amid the COVID-19 pandemic. Open Forum Infect Dis. 2021;9:ofab618.